Abstract
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, show dramatic effects against non-small cell lung cancer (NSCLC) with EGFR activating mutations. However, 25% – 30% of EGFR mutant lung cancer patients show intrinsic resistance, and the responders almost invariably acquire resistance to EGFR-TKIs within several years. Three mechanisms — second-site point mutation that substitutes methionine for threonine at position 790 (T790M) in EGFR, amplification of MET protooncogene, and overexpression of hepatocyte growth factor (HGF, a ligand of MET) — have been reported to contribute to resistance to EGFR-TKIs. These three factors were detected simultaneously in a population of patients with acquired resistance to EGFR-TKIs. Further investigations to develop optimal therapy based on accurate diagnosis of resistant mechanism are warranted to improve the prognosis of EGFR mutant lung cancer.
Keywords: Acquired resistance, EGFR mutation, gene amplification, lung cancer, tyrosine kinase inhibitor, HGF, gefitinib, erlotinib, intrinsic resistance, T790M mutation, Met amplification, fibroblasts, microenvironment, EGFR-TKI, ErbB3, PI3K, Akt
Current Signal Transduction Therapy
Title: HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer
Volume: 6 Issue: 2
Author(s): Seiji Yano, Wei Wang, Qi Li, Tadaaki Yamada, Shinji Takeuchi, Kunio Matsumoto, Yasuhiko Nishioka and Saburo Sone
Affiliation:
Keywords: Acquired resistance, EGFR mutation, gene amplification, lung cancer, tyrosine kinase inhibitor, HGF, gefitinib, erlotinib, intrinsic resistance, T790M mutation, Met amplification, fibroblasts, microenvironment, EGFR-TKI, ErbB3, PI3K, Akt
Abstract: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, show dramatic effects against non-small cell lung cancer (NSCLC) with EGFR activating mutations. However, 25% – 30% of EGFR mutant lung cancer patients show intrinsic resistance, and the responders almost invariably acquire resistance to EGFR-TKIs within several years. Three mechanisms — second-site point mutation that substitutes methionine for threonine at position 790 (T790M) in EGFR, amplification of MET protooncogene, and overexpression of hepatocyte growth factor (HGF, a ligand of MET) — have been reported to contribute to resistance to EGFR-TKIs. These three factors were detected simultaneously in a population of patients with acquired resistance to EGFR-TKIs. Further investigations to develop optimal therapy based on accurate diagnosis of resistant mechanism are warranted to improve the prognosis of EGFR mutant lung cancer.
Export Options
About this article
Cite this article as:
Yano Seiji, Wang Wei, Li Qi, Yamada Tadaaki, Takeuchi Shinji, Matsumoto Kunio, Nishioka Yasuhiko and Sone Saburo, HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer, Current Signal Transduction Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157436211795659928
DOI https://dx.doi.org/10.2174/157436211795659928 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metallothioneins and Platinum(II) Anti-Tumor Compounds
Current Medicinal Chemistry Assessment of the Usefulness of the SEMA5A Concentration Profile Changes as a Molecular Marker in Endometrial Cancer
Current Pharmaceutical Biotechnology Carbon Nanotubes: Classification, Method of Preparation and Pharmaceutical Application
Current Drug Delivery Innovative Treatment Approach for Cancer-Related Cachexia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthesis, Neuro-protection and Anti-cancer Activities of Simple Isatin Mannich and Schiff Bases
Letters in Drug Design & Discovery Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Toll-Like Receptors: Cost or Benefit for Cancer?
Current Pharmaceutical Design In vivo Cancer Imaging with Semiconductor Quantum Dots
Current Pharmaceutical Analysis The Potential for Targeting Oncogenic WNT/β -Catenin Signaling in Therapy
Current Drug Targets The Role of Pemetrexed in Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer
Current Drug Targets Tumor Stroma Manipulation By MSC
Current Drug Targets Tumor-Targeting Peptides and Small Molecules as Anti-Cancer Agents to Overcome Drug Resistance
Current Medicinal Chemistry From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design It Takes Two to Tango: The Structure and Function of LIM, RING, PHD and MYND Domains
Current Pharmaceutical Design Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Development and Pharmacological Evaluation of a PEG Based Nanoparticulate Camptothecin Analog for Oral Administration
Current Drug Delivery Histone Deacetylase Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Status of Non-Classical Mononuclear Platinum Anticancer Drug Development
Mini-Reviews in Medicinal Chemistry Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
Current Cancer Therapy Reviews The Relationship Between Prostate Cancer and Metformin Consumption: A Systematic Review and Meta-analysis Study
Current Pharmaceutical Design